PLGA NHS Capped, MW 10K (PLGA‑NHS) is a high‑molecular‑weight, amine‑reactive biodegradable PLGA copolymer functionalized with terminal N‑hydroxysuccinimide (NHS) ester groups. Featuring enhanced structural rigidity, excellent morphological stability and prolonged hydrolytic degradation performance, this polymer retains high-efficiency amine-specific covalent conjugation activity. It serves as a high-performance reactive building block for long-cycle sustained drug delivery, high-stability nanoparticle functionalization and long-term biomedical modification research.
Basic Specifications
Alternative Name: PLGA‑NHS, PLGA N‑hydroxysuccinimide Capped
Polymer Composition: Poly(D,L‑lactide‑co‑glycolic acid)‑NHS
Molecular Weight: 10K, Custom
Appearance: White to off‑white solid
Key Features and Benefits
Highly Active Terminal NHS Ester Reactivity: Modified with high-purity terminal NHS ester functional groups, enabling efficient, high-specificity covalent conjugation with primary amine (-NH₂) groups under mild physiological conditions. The reaction forms stable, irreversible amide bonds with negligible non-specific binding and side reactions, ensuring durable and reliable covalent modification of antibodies, therapeutic proteins, functional peptides and amine-terminated targeting ligands for long-cycle experiments.
Enhanced 10K High Molecular Weight Performance: The 10K high molecular weight forms dense polymer chain entanglement, delivering significantly improved structural rigidity, anti-deformation capability and morphological stability compared to medium and low-MW PLGA polymers. It features uniform, prolonged hydrolytic degradation kinetics, effectively preventing nanoparticle rupture, structural fatigue and premature drug leakage, perfectly suited for long-cycle sustained-release formulations and high-stability carrier preparation.
Excellent Biocompatibility & Long-Term Uniform Degradation: Possesses superior physiological biocompatibility and biosafety. The PLGA backbone undergoes mild, uniform hydrolysis into endogenous non-toxic lactic acid and glycolic acid throughout the long degradation cycle, with no inflammatory stimulation, tissue irritation or residual toxicity. It fully meets strict biosafety standards for long-term in vivo biomedical applications and sustained-release formulation research.
Long-Term Stable Conjugation Efficiency: Precision terminal NHS capping technology ensures uniform reactive group distribution and persistent batch-to-batch activity. The robust amide covalent bond maintains excellent chemical stability during long-term polymer degradation, effectively avoiding ligand shedding and functional attenuation, ensuring stable, repeatable results for long-cycle biomedical experiments and formulations.
High-Stability Functional Modification Compatibility: The mild amine-specific reaction mechanism supports flexible post-synthesis functionalization of high-stability nanoparticles and implantable biomedical scaffolds. It protects the biological activity of modified biomolecules and the structural integrity of carriers, perfectly adapting to long-term advanced biomedical research scenarios.
Applications
Long-Cycle Amine‑Specific Bioconjugation: Widely applied for durable covalent modification and immobilization of amine-rich antibodies, therapeutic proteins, functional peptides and targeted ligands, supporting stable long-term biomolecule assembly and persistent biomedical probe preparation.
Long-Cycle Sustained Targeted Drug Delivery: Ideal for fabricating high-stability PLGA nanoparticles and microspheres, achieving uniform long-cycle sustained drug release and stable active targeted delivery, suitable for chronic disease treatment and long-acting controlled-release pharmaceutical formulation development.
High-Stability Nanoparticle Surface Functionalization: Serves as a high-performance reactive precursor for advanced biodegradable carrier surface engineering, stably immobilizing targeting functional groups to enhance carrier structural durability, in vivo circulation stability and targeted accumulation efficiency.
Long-Term Advanced Biomedical Research: Applicable for high-stability biomaterial modification, long-cycle sustained-release system construction and persistent biological labeling research, providing reliable reactive performance for high-standard long-term biomedical experimental workflows.
Storage and Handling
Storage: Store at –20 °C in a fully sealed, dry, moisture‑proof container. Inert gas sealing is strongly recommended for long‑term storage to prevent NHS ester hydrolysis and preserve polymer reactive activity and structural integrity.
Handling: Strictly avoid moisture intrusion, high‑temperature environments and prolonged air exposure, as NHS groups are highly moisture‑sensitive and prone to deactivation. Avoid repeated freeze‑thaw cycles to maintain stable conjugation efficiency.
PLGA NHS Capped, MW 10K integrates high stable amine-specific NHS reactivity, enhanced structural rigidity and long-cycle degradability, acting as a high-performance reactive biodegradable polymer for long-term bioconjugation, long-cycle sustained targeted drug delivery and high-stability biomaterial functional modification research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.